RecoveryInvestigational

GHK (Glycyl-Histidyl-Lysine)

Topical, Subcutaneous injection

Overview

GHK is a naturally occurring tripeptide with high affinity for copper ions, forming the GHK-Cu complex. It is present in human plasma, saliva, and urine at concentrations that decline with age.

Mechanism of Action

The peptide modulates extracellular matrix remodeling, metalloproteinase activity, and growth factor signaling, contributing to wound healing and tissue repair processes..

Research Summary & Key Findings

In vitro studies have demonstrated enhanced collagen synthesis, angiogenesis, and antioxidant enzyme expression in cultured fibroblasts. Animal wound healing models have shown accelerated closure and improved tissue organization with topical or systemic GHK-Cu administration. Small human studies in dermatology have reported improvements in photoaging and skin elasticity, but large randomized controlled trials are lacking.

Clinical Status

Investigational

GHK (Glycyl-Histidyl-Lysine) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

TopicalSubcutaneous injection

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers GHK (Glycyl-Histidyl-Lysine) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply GHK (Glycyl-Histidyl-Lysine).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.